|

Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy

RECRUITINGSponsored by First Hospital of China Medical University
Actively Recruiting
SponsorFirst Hospital of China Medical University
Started2024-01-01
Est. completion2026-12-31
Eligibility
Age18 Years – 80 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06282796

Summary

This multicenter clinical study aims to build an intelligent and accurate diagnosis and dynamic prediction and early warning model of cardiotoxicity due to anthracycline-based breast cancer chemotherapy, clarify the value of the early warning model in guiding the targeted prevention of myocardial protection, providing an important theoretical basis for reducing the mortality rate of breast cancer and improving the prognosis.

Eligibility

Age: 18 Years – 80 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Age ≥18 years
* Histologically or cytopathological confirmed stage I-III HER2+ breast cancer, scheduled to receive consecutive anthracycline chemotherapy or subsequent sequential trastuzumab targeted therapy
* LVEF≥53% before chemotherapy

Exclusion Criteria:

* life expectancy ≤12 months
* Participating in other ongoing oncology clinical trials
* Prior treatment with anthracyclines or chest radiation therapy
* Pregnant or lactating women
* Ultrasound images of the heart are of very poor quality

Conditions3

Breast CancerCancerHeart Disease

Browse More Trials

Cancer trialsHeart Disease trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.